Eclipse Bio
Eclipse Bio (Eclipsebio) is a life sciences company that provides RNA biology expertise and proprietary analytical technologies for drug developers and researchers. The company's eCOMPASS platform integrates AI-powered sequence design, rapid prototyping, and sequencing-first analytics into an iterative design-make-characterize workflow for RNA drug development. Eclipsebio offers a suite of proprietary assays…
Funding snapshot
About
Eclipse Bio (Eclipsebio) is a life sciences company that provides RNA biology expertise and proprietary analytical technologies for drug developers and researchers. The company's eCOMPASS platform integrates AI-powered sequence design, rapid prototyping, and sequencing-first analytics into an iterative design-make-characterize workflow for RNA drug development. Eclipsebio offers a suite of proprietary assays including eSHAPE for RNA structure determination, m6A-eCLIP for methylation mapping, miR-eCLIP+ for miRNA binding identification, and Nanopore long-read sequencing, all providing nucleotide-level resolution. The company serves developers of RNA therapeutics, small oligonucleotides, small molecules targeting RNA, and AI training data for drug discovery through its eVERSE platform. Over 300 partners across pharma, biotech, and academia trust Eclipsebio's analytics. Founded in 2017 and headquartered in San Diego, California, the company has raised $18.9M in Series A funding from investors including Alexandria, Phoenix Venture Partners, and IGlobe Partners.
Business model
Genomics > Enabling Technologies > Suite
Team background
College Wise > Massachusetts Institute of Technology, University of Toronto, Stanford University
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.